Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Urogen Pharma Ltd Ordinary Shares (URGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Jones "Woody" Bryan Joins UroGen Pharma as Senior Vice President of Business Development

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company, today announced that Jones "Woody" Bryan, Ph.D. has been appointed as Senior Vice President of Business Development....

URGN : 45.04 (+0.07%)
UroGen Pharma Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 14, 2018 / UroGen Pharma Ltd. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern Time.

URGN : 45.04 (+0.07%)
UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer

Life Sciences Veteran Brings Extensive Global Finance, Commercial Operations and Business Development Experience to Prepare UroGen for its Transition from a Clinical Stage Company to Commercialization

URGN : 45.04 (+0.07%)
UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET

URGN : 45.04 (+0.07%)
UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel(TM)) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)

Company Expects to Begin U.S. Phase 2b Clinical Trial in Q3 2018

URGN : 45.04 (+0.07%)
UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors

Tomasello is a Renowned Industry Expert Responsible for the Commercialization of Revolutionary, Multi-Billion Dollar Products in Hematology-Oncology

URGN : 45.04 (+0.07%)
UroGen Pharma's Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Arie...

URGN : 45.04 (+0.07%)
UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments

Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel(TM)) for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) to be Presented at American Urological Association (AUA)...

URGN : 45.04 (+0.07%)
UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET

URGN : 45.04 (+0.07%)
Factors of Influence in 2018, Key Indicators and Opportunity within Dorman Products, Arch Capital Group, Acacia Communications, UROGEN PHARMA, CyrusOne, and TCP Capital -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dorman Products, Inc. (NASDAQ:DORM),...

URGN : 45.04 (+0.07%)
ACIA : 38.78 (-0.82%)
TCPC : 14.24 (-0.07%)
DORM : 79.23 (-0.46%)
ACGL : 30.24 (+0.20%)
CONE : 68.56 (+0.50%)
Today's Research Reports on Stocks to Watch: UroGen Pharma and Novartis

NEW YORK, NY / ACCESSWIRE / April 4, 2018 / Shares of Novartis and UroGen both saw gains in Tuesday trading. UroGen saw its shares climb after announcing new data presentation from an interim analysis...

URGN : 45.04 (+0.07%)
NVS : 85.03 (-0.12%)
UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel(TM)) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced a new data...

URGN : 45.04 (+0.07%)
Research Report Identifies Prothena, UROGEN PHARMA, Mizuho Financial Group, 1-800 FLOWERS.COM, Willis Towers Watson Public, and First Connecticut with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Prothena Corporation PLC (NASDAQ:PRTA),...

WLTW : 146.09 (-0.18%)
FLWS : 11.05 (+3.27%)
URGN : 45.04 (+0.07%)
FBNK : 30.10 (-0.99%)
PRTA : 13.21 (+4.02%)
MFG : 3.53 (unch)
UroGen Reports Fourth Quarter and Full Year 2017 Financial Results

Presentation of MitoGel(TM) Interim Analysis from OLYMPUS Pivotal Trial in Patients with Low Grade Upper Tract Urothelial Cancer Planned at Upcoming Medical Meeting

URGN : 45.04 (+0.07%)
UroGen Pharma to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 15, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET

URGN : 45.04 (+0.07%)
UroGen to Present at March 2018 Investor Conferences

UroGen Pharma Ltd. (NASDAQ:URGN) today announced that management plans to present at two investor conferences in March 2018:

URGN : 45.04 (+0.07%)
UroGen Pharma to Present at the Jefferies 2017 London Healthcare Conference

URGN : 45.04 (+0.07%)
UroGen Pharma to Host Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017

URGN : 45.04 (+0.07%)
UroGen Pharma to Host Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017

UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that the...

URGN : 45.04 (+0.07%)
UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel(TM) in Combination with BOTOX(R) for the Treatment of Overactive Bladder

URGN : 45.04 (+0.07%)
AGN : 186.07 (+0.97%)

Van Meerten Stock Picks

Tesla According to Peter Lynch
Today's Barchart Chart of the Day will be the auto maker Tesla (TSLA).
TSLA -9.88
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

cmdty Insider - Ag Market Commentary

Today's Commentary

Corn futures are trading fractionally lower this morning. They ended the Monday session with most contracts 3 to 4 cents in the red. December posted a new life of contract low. The weekly Export Inspections report showed US corn shipments for the wee...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar